A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Piclidenoson (Primary)
- Indications Intermediate uveitis; Posterior uveitis
- Focus Therapeutic Use
- Sponsors Can-Fite BioPharma
- 30 Jan 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Jan 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2019.
- 23 Jan 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.